Phospholipid binding antibody syndrome: From recognition of phospholipids to that of phospholipid-protein complexes;Syndrome des antiphospholipides: De la reconnaissance des phospholipides a celle des 'antiphospholipides-proteines'

Hematologie

Volumn 2, Issue 3, 1996, Pages 203-210

  Carreras, Luis ^a   Forastiero, Ricardo ^a   Falcón, Cristina ^a   Maclouf, Jacques ^b  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN FAVALORO   (Argentina)

^b HÔPITAL LARIBOISIÈRE   (France)

Author keywords

2 glycoprotein I; eicosanoids; lupus anticoagulant; protein C; tissue factor

Indexed keywords

BETA2 GLYCOPROTEIN; ICOSANOID; LUPUS ANTICOAGULANT; PROTEIN C; THROMBOPLASTIN; UNCLASSIFIED DRUG;

ANTIPHOSPHOLIPID SYNDROME; HUMAN; REVIEW;

EID: 0029946806     PISSN: 12647527     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Harris EN. The antiphospholipid syndromean introduction. In: Harris EN, Exner T, Hugues GRV, Asherson RA, eds. Phospholipid binding antibodies. Boca Raton, Florida: CRC Press, 1991 : 373-86.
2. Conley CL, Hartman RC. A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematous, J Clin Invest 1952; 31: 621-2.
3. Bowie EJW, Thompson JH, Pascuzzi CA, Owen CA. Thrombosis in SLE despite circulating anticoagulants. J Lab Clin Med 1963; 62: 416-30.
4. Vianna JL, Khamashta MA, Ordi-Ros J, Font J, Cervera R, Lopez-Soto A, Tolosa C, Franz J, Selva A, Ingelmo M, Vilardell M, Hugues GRV. Comparison of the primary and secondary antiphospholipid syndrome : a European multicenter study of 114 patients. Am J Med 1994; 96: 3-9.
5. Love PE, Santoro SA. Antiphospolipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Ann Intern Med 1990; 112: 682-98.
6. Branch DW. Immunologic disease and fetal death. Clin Obstet Gynecol 1987; 30: 295-311.
7. Thiagarajan P, Shapiro SS, De Marco L. Monoclonal immunoglobulin M λ coagulation inhibitor with phospholipid specificity: mechanism of a lupus anticoagulant. J Clin Invest 1980; 66: 397-405.
8. Harris EN, Gharavi AE, Loizou S, et al. Cross-reactivity of antiphospholipid antibodies. J Clin Lab Immunol 1985; 16 : 1-6.
9. Rauch J, Tannenbaum H, Janoff AS. Distinguishing plasma lupus anticoagulants from antifactor antibodies using hexagonal (II) phase phospholipids. Thromb Haemostas 1989; 62: 892-6.
10. Vermylen J, Amout J. Is the antiphospholipid syndrome caused by antibodies directed against physiologically relevant phospholipid-protein complexes? J Lab Clin Med 1992; 120: 10-2.
11. Triplett DA. Assays for detection of antiphospholipid antibodies. Lupus 1994; 3: 281-7.
12. Harris EN. The second international anticardiolipin standardization workshop/The Kingston antiphospholipid antibody study (KAPS) group. Am J Clin Pathol 1990; 94: 476-84.
13. Falcon CR, Hoffer AM, Forastiero RR, Carreras LO. Clinical significance of various EUSA assays for detecting antiphospholipid antibodies. Thromb Haemostas 1990; 64: 21-5.
14. Carreras LO, Defreyn G, Machin SJ, Vermylen J, Deman R, Spitz B, Van Assche A. Arterial thrombosis, intrauterine death and « lupus » anticoagulant: detection of immunoglobulin interfering with prostacyclin formation. Lancet 1981 ; 1 : 244-6.
15. Watson KV, Schoter AE. Lupus anticoagulant inhibition of in vitro prostacyclin release is associated with a thrombosis-prone subset of patients. Am J Med 1991; 90: 47-53.
16. 2 activity. J Lab Clin Med 1992; 120: 67-77.
17. Walker TS, Triplett DA, Javed N, Musgrave K. Evaluation of lupus anticoagulants: antiphospholipid antibodies, endothelium-associated immunoglobulin, endothelial prostacyclin secretion and antigenic protein S levels. Thromb Res 1988; 51: 267-81.
18. Hasselaar P, Derksen RHWM, Blokzijl L, de Groot PG. Thrombosis associated with antiphospholipid antibodies cannot be explained by effects on endothelial and platelet prostanoid synthesis, Thromb Haemostas 1988; 59: 80-5.
19. Lellouche F, Martinuzzo M, Said P, Maclouf J, Carreras LO. Imbalance of thromboxane/prostacyclin biosynthesis in patients with lupus anticoagulant. Blood 1991; 78: 2894-9.
20. Martinuzzo ME, Maclouf J, Carreras LO, Lévy Toledano S. Antiphospholipid antibodies enhance thrombin-induced platelet activation and thromboxane formation. Thromb Haemostas 1993; 70: 667-71.
21. Lin YL, Wang CT. Activation of human platelets by the rabbit anticardiolipin antibodies. Blood 1992; 80: 3135-43.
22. Reverter JC, Tàssies D, Escolar G, Font J, Soto AL, Ingelmo M, Ordinas A. Effect of plasma from patients with primary antiphospholipid syndrome on platelet function in a collagen rich perfusion system. Thromb Haemostas 1995; 73: 132-7.
23. Campbell AL, Pierangeli SS, Welhausen S, Harris EN. Comparison of the effects of anticardiolipin antibodies from patients with the antiphospholipid syndrome and with syphilis on platelet activation and aggregation. Thromb Haemostas 1995; 73: 529-34.
24. Habib A, Martinuzzo ME, Carreras LO, Levy-Toledano S, Maclouf J. Increased expression of inducible cyclooxigenase-2 in human endothelial cells by antiphospholipid antibodies. Thromb Haemostas 1995; 74: 770-7.
25. Comp PC, DeBault LE, Esmon NL, Esmon CT. Human thrombomodulin is inhibited by IgG from two patients with non-specific anticoagulants. Blood 1983; 62: 299 (Abstr.).
26. Cariou R, Tobelem G, Bellucci S, Soria J, Soria C, Maclouf J, Caen J. Effect of lupus anticoagulant on antithrombogenic properties of endothelial cells. Inhibition of thrombomodulin-dependent protein C activation. Thromb Haemostas 1988; 60: 54-8.
27. 2-glycoprotein 1, show negligible effects on endothelial cell mediated protein C activation. Thromb Haemostas 1991; 66: 666-71.
28. a by activated protein C on human endothelial cells. Thromb Haemostas 1992; 68: 268-72.
29. Smimov MD, Triplett DT, Comp PhC, Esmon NL, Esmon ChT. On the role of phosphati-dylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies, J Clin Invest 1995; 95: 309-16.
30. Oosting JD, Derksen RHWM, Bobbink IWG, Hackeng TM, Bouma BN, de Groot PG. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C or protein S : an explanation for their pathogenic mechanism? Blood 1993; 81: 2618-25.
31. Forastiero RR, Kordich L, Basilotta E, Carreras LO. Differences in protein S and C4b-binding protein levels in different groups of patients with antiphospholipid antibodies. Blood Coog Fibrinol 1994; 5: 609-16.
32. Hasselaar P, Derksen RHWM, Oosting JD, Blokzijl L, de Groat PG. Synergistic effect of low doses of tumor necrosis factor and sera from patients with systemic lupus erythematosus on the expression of procoagulant activity by cultured endothelial cells. Thromb Haemostas 1989; 62: 654-60.
33. Branch DW, Rodgers GM. Induction of endothelial cell tissue factor activity by sera from patients with antiphospholipid syndrome: a possible mechanism of thrombosis. Am J Obstet Gynecol 1993; 168: 206-10.
34. Kornberg A, Blank M, Kaufman S, Shoenfeld Y. Induction of tissue factor-like activity in monocytes by anticardiolipin antibodies. J Immunol 1994; 153: 1328-32.
35. Francis RB, McGehee WG, Feinstein DI. Endothelial-dependent fibrinolysis in subjects with the lupus anticoagulant and thrombosis. Thromb Haemostas 1988; 59: 412-4.
36. Keeling DM, Campbell SJ, Mackie IJ, Machin SJ, Isenberg DA. The fibrinolytic response to venous oclussion and the natural anticoagulants in patients with antiphospholipid antibodies both with and without systemic lupus erythematosus. Br J Haematol 1991; 77: 354-9.
37. Tsakiris DA, Marbet GA, Makris PE, Settas L, Duckert F. Impaired fibrinolysis as an essential contribution to thrombosis in patients with lupus anticoagulant. Thromb Haemostas 1989; 61: 175-7.
38. Violi F, Ferro D, Valesini G, Quintarelli C, Saliola M, Grandilli MA, Balsano F. Tissue plasminogen activator inhibitor in patients with systemic lupus erythematosus and thrombosis. Br Med J 1990; 300: 1099-102.
39. Matsuda J, Saitoh N, Gohchi K, Gotoh M, Tsukamoto M. Anti-annexin V antibody in systemic lupus erythematosus patients with lupus anticoagulant and/or anticardiolipin antibody. Am J Hematol 1994; 47: 56-8.
40. Sammaritano LR, Ghoravi AE. Antiphospholipid antibodies and placental anticoagulant protein I. Lupus 1994; 3: 263-5.
41. Shibata S, Harpel PC, Gharavi A, Raud J, Fillit H. Autoantibodies to heparin from patients with antiphospholipid antibody syndrome inhibit formation of antithrombin III-thrombin complexes. Blood 1994; 83: 2532-40.
42. Branch DW, Dudley DJ, Mitchell MD, Creightari KA, Abott JM, Hammond EH, Daynes RA. Immunoglobulin C fractions from patients with antiphospholipid antibodies caused fetal death in Balb/c mice : a model for autoimmune fetal loss. Am J Obstet Gynecol 1990; 163: 210-6.
43. Blank M, Cohen J, Toder V, Shoenfeld Y. Induction of antiphospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anticardiolipin antibodies. Proc Natl Acad Sci USA 1991; 88: 3069-73.
44. Bakimer R, Fishman P, Blank M, Srednc B, Djaldetti M, Shoenfeld Y. Induction of primary antiphospholipid syndrome in mice by immunization with a human monoclonal anticardiolipin antibody (H-3). J Clin Invest 1992; 89: 1558-63.
45. Blank M, Tincani A, Shoenfeld Y. Induction of experimental antiphospholipid syndrome in naive mice with purified IgG antiphosphatidylserine antibodies. J Rheumatol 1994; 21: 100-4.
46. Pierangeli SS, Barker JH, Stikovac D, Anderson G, Ackerman D, Barquinero J, Acland R, Harris EN. Effect of human IgG antiphospholipid antibodies on an in vivo thrombosis model in mice. Thromb Haemostas 1994; 71: 670-4.